From the desk of Jorge D. Faccinetti – chief editor and co-founder – I am thrilled to announce that Pituitary World News co-founder Dr. Lewis Blevins has been working on a new book on Cushing’s
A new book. Stay tuned!
April 1, 2024
Industry News
News from pharmaceutical companies and other related healthcare organizations
Big news for acromegaly at Crinetics
July 12, 2021
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Two clinical trials for acromegaly patients: see if you are eligible.
May 10, 2021
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers
The Road to MYCAPSSA: A Conversation with Dr. Bill Ludlam
January 26, 2021
We recently had a chance to sit down with Chiasma Inc.’s Senior VP of Clinical Development & Medical Affairs, Dr. Bill Ludlam, to discuss his career and his work in rare diseases. Dr. Ludlam played
Hello, Pills!
September 7, 2020
With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed 58% of patients maintained normal IGF-1 levels with the new oral
Crinetics new drug candidate for acromegaly Paltusotine awarded Orphan Drug Designation
July 30, 2020
From a Crinetics Pharmaceutical press release: Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced that the
More information on Recordati’s new Cushing’s drug Isturisa
July 30, 2020
In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and Endocrinology. “The exciting data, published today, underscore the efficacy and safety
More news on Isturisa for Cushing’s
June 10, 2020
In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States, announced the full availability of Isturisa® for the treatment of adult
From Endocrine Web: New Oral Acromegaly Treatment Has No Needles Required
May 14, 2020
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,
A new drug for Cushing’s: Learn more
April 22, 2020
In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing’s disease recently approved in the US.
Exciting news for acromegaly and NET’s from Crinetics Pharmaceuticals!
April 9, 2020
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine
News on Signifor, Signifor LAR, and newly approved Cushing’s drug ISTURISA
April 8, 2020
Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products treat pituitary diseases. SIGNIFOR LAR, a “2nd generation” somatostatin analog given
Questions about access to therapies, financial assistance?
March 30, 2020
If you are currently taking, or are about to start taking Lanreotide (Somatuline Depot) injections, this website from Ipsen offers a wealth of information about patient access to therapies. IPSEN CARES serves as a central